Scalable Actinium-225 supply for clinical and commercial success
Eckert & Ziegler has established one of the world’s first commercial, GMP-compliant production lines for Actinium-225. With our certified cyclotron-based process and global infrastructure, we are committed to supporting radiopharmaceutical developers and manufacturers as they advance targeted alpha therapies from bench to bedside.
Regular production runs ensure steady availability of GMP- and non-GMP-grade. Secure your supply now and partner THE independent isotope supplier.
Key Features
Production Process
Our production uses a proprietary cyclotron-based method, irradiating Radium-226 targets to produce non-carrier-added Actinium-225. This innovative technology in combination with an extensive purification process enables highly pure Ac-225 with minimal contaminations of long-lived isotopes such as Actinium-227 and Thorium-229 – ideal for therapeutic use. Operations have successfully been validated for GMP compliance.
Applications
Our Actinium-225 is suitable for radiolabeling peptides, antibodies, and small molecules used in the development of targeted alpha therapies for oncology and beyond. It supports applications in early-phase research, and our GMP material serves your late-stage trials and commercial deployment.
Supply & Logistics
With a central European production hub and a global logistics network, we offer flexible delivery, secure transport, and full regulatory support. Early reservation options and scalable output help you stay ahead of clinical and commercial demand.
Beyond Supply
Eckert & Ziegler also offers CDMO services, hot cell solution and synthesis as well as quality control equipment to streamline your path from isotope to finished product. Our expertise covers the full alpha therapy value chain. Learn more about our alpha expertise! >>>